Max Winokan
Papers
1
Total Citations
2
H-Index
1
About
Max Winokan is a rising figure in computational chemistry and structure-based drug discovery, whose work centers on fragment-based design and synthetic accessibility. His most notable contribution is the development of **Syndirella**, a computational platform introduced in his 2025 paper that enables synthesis-directed fragment elaboration. This tool allows researchers to explore extensive binding site landscapes beyond pre-existing catalog compounds, addressing a critical bottleneck in early-stage drug discovery: the need to maximize compound diversity and interaction sampling without prematurely converging on suboptimal scaffolds. By integrating synthetic feasibility directly into the design process, Syndirella empowers medicinal chemists to generate more chemically tractable and information-rich derivatives from fragment screening hits. Though early in his career, Winokan’s work has already garnered attention for its practical impact on rational ligand design. His approach exemplifies how computational methods can bridge the gap between fragment-based screening data and the rapid exploration of chemical space, making him a promising voice in the next generation of drug discovery researchers.
Research Focus
Key Achievements
Top Papers
- 1